MACH15Moderate Alcohol and Cardiovascular Health Trial
Alcohol
Maladies Cardiovasculaires+3
+ Diabète Mellitus
+ Maladies du système endocrinien
Étude de prévention
Résumé
Date de début de l'étude : 5 février 2018
Date à laquelle le premier participant a commencé l'étude.The Moderate Alcohol and Cardiovascular Health Trial (MACH15) is a multicenter, worldwide, randomized clinical trial of \~15 gm of alcohol daily versus abstention, using a balanced parallel design and single-blind assessment of all outcomes among approximately 7,800 participants aged 50 years and older with advanced cardiovascular risk. Intervention will average 6 years in duration with a common close-out date. Following recruitment and pre-screening, participants will attend a screening visit followed by a two-week abstention washout period, a baseline visit and randomization, and subsequent visits at 3 months, 6 months, 12 months, and then annually until close-out.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.103 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Prévention
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 50 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Conditions
Pathologie
Critères
Inclusion Criteria: * Age ≥50 years at screening * Postmenopausal, defined as 12 consecutive months without menstruation * Not alcohol naïve, defined by having consumed at least one drink of alcohol in the past five years * High risk for the occurrence of a new cardiovascular disease event, defined as having any one of the following: 1. American Heart Association (AHA)/American College of Cardiology (ACC) Risk Score ≥15% within the past 24 months (among those without clinical or subclinical cardiovascular disease \[CVD\]) 2. Clinical CVD (more than 6 months prior to randomization), defined by: 1. Previous myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), carotid endarterectomy (CE), carotid stenting; 2. Peripheral artery disease (PAD) with revascularization; 3. Acute coronary syndrome with or without resting electrocardiogram (ECG) change, ECG changes on a graded exercise test (GXT), or positive cardiac imaging study; 4. Prior stroke documented on brain imaging or with a persistent deficit. 3. Subclinical CVD, confirmed in available medical records: 1. At least a 50% diameter stenosis of a coronary, carotid, or lower extremity artery; 2. Coronary artery calcium score ≥400 Agatston units; 3. Ankle brachial index (ABI) ≤0.90; 4. Left ventricular hypertrophy (LVH) by ECG (based on computer reading), echocardiogram report, or other cardiac imaging procedure report; 5. Abdominal aortic aneurysm (AAA) ≥5 cm with or without repair. Exclusion Criteria: * High alcohol consumption, defined by any one of the following: 1. Alcohol Use Disorders Identification Test (AUDIT) score \>5 at screening 2. Drinking, on average, \>7 alcoholic beverages/week during the past 6 months 3. Drinking 6 or more alcoholic beverages on one occasion during the past 6 months * Yale-Brown Obsessive Compulsive Scale-heavy drinking (Y-BOCS-hd) total score of ≥6 on questions 7, 8, and 10 * Cardiovascular disease event (MI, revascularization procedure, or stroke) within the 6 months prior to randomization * AHA Class III-IV heart failure * History of alcohol or substance abuse (medical record confirmed or self-reported history) * Other intolerance or allergy to alcohol * Dual antiplatelet therapy * History of gastric bypass surgery * Any serious chronic liver disease (e.g., active hepatitis B and C infections) or liver tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\] and gamma-glutamyl transpeptidase \[GGT\]) \>2 times the upper limit of the normal range using local standards * Personal history of any colon or liver cancer * Any other cancer with a life expectancy of less than 3 years * Diagnosed with breast cancer that required either surgery or removal of breast tissue or chemotherapy * Mother or sister ever diagnosed with breast cancer that required either surgery or removal of breast tissue or chemotherapy * Estimated glomerular filtration rate (eGFR) \<30 ml/min /1.73m2 or end-stage renal disease (ESRD) * Ongoing use of any medication for which alcohol consumption is contraindicated * A Patient Health Questionnaire (PHQ-9) ≥15 at screening * History of any organ transplant * Unintentional weight loss \>10% in last 6 months * Currently participating in another clinical trial (intervention trial) with CVD outcomes. Note: Participant must wait until the completion of his/her activities or the completion of the other trial before being screened for MACH15. Local restrictions for entry by participants can be more conservative if mandated. * Not willing or able to provide a name and contact information for at least one additional contact person other than self * Investigator discretion regarding appropriateness of participation or concern about intervention adherence, including: 1. moderate - severe psychiatric illness 2. behavioral concerns regarding likelihood of low adherence to trial protocol 3. a medical condition likely to limit survival to less than 3 years 4. advanced chronic disease, such as dementia, that requires 24-hour care * Not willing or able to provide a signed and dated informed consent form * Not willing or able to comply with all trial procedures.
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.Un seul groupe d'intervention est désigné dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
Comparateur actifObjectifs de l'étude
Objectifs principaux
Objectifs secondaires
Centres d'étude
Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.Cette étude comporte 4 sites
Johns Hopkins ProHealth Clinical Research Center
Baltimore, United StatesOuvrir Johns Hopkins ProHealth Clinical Research Center dans Google MapsWake Forest Sticht Center on Aging
Winston-Salem, United StatesJulius Clinical
Zeist, NetherlandsCenter for Bioethics and Research
Ibadan, Nigeria